牛牛AI助理已提取核心訊息
NeuroSense Therapeutics Ltd., a foreign private issuer, has submitted a Form 6-K report to the United States Securities and Exchange Commission (SEC) for January 2024. The report includes an updated presentation of the company's business, which has been made publicly available as Exhibit 99.1. Notably, the presentation contains newly updated information on slides 4 and 29. NeuroSense emphasizes that the new data in the presentation does not constitute an admission of materiality. The company advises that the presentation's summary information should be viewed in conjunction with its SEC filings and other public disclosures, which may include press releases. The updated presentation is dated January 2024, and the Form 6-K was signed on behalf of NeuroSense Therapeutics Ltd. by Alon Ben-Noon on January 9, 2024.
NeuroSense Therapeutics Ltd., a foreign private issuer, has submitted a Form 6-K report to the United States Securities and Exchange Commission (SEC) for January 2024. The report includes an updated presentation of the company's business, which has been made publicly available as Exhibit 99.1. Notably, the presentation contains newly updated information on slides 4 and 29. NeuroSense emphasizes that the new data in the presentation does not constitute an admission of materiality. The company advises that the presentation's summary information should be viewed in conjunction with its SEC filings and other public disclosures, which may include press releases. The updated presentation is dated January 2024, and the Form 6-K was signed on behalf of NeuroSense Therapeutics Ltd. by Alon Ben-Noon on January 9, 2024.
外國私人發行人NeuroSense Therapeutics Ltd. 已向美國證券交易委員會（SEC）提交了2024年1月的6-K表格報告。該報告包括公司業務的最新介紹，該報告已作爲附錄99.1公開發布。值得注意的是，該演示文稿包含幻燈片 4 和 29 上的最新信息。NeuroSense強調，演示文稿中的新數據並不構成對重要性的承認。該公司建議，該演示文稿的摘要信息應與其向美國證券交易委員會提交的文件和其他公開披露（可能包括新聞稿）一起查看。更新的演示文稿的日期爲2024年1月，Alon Ben-Noon於2024年1月9日代表NeuroSense Therapeutics Ltd.簽署了6-K表格。
外國私人發行人NeuroSense Therapeutics Ltd. 已向美國證券交易委員會（SEC）提交了2024年1月的6-K表格報告。該報告包括公司業務的最新介紹，該報告已作爲附錄99.1公開發布。值得注意的是，該演示文稿包含幻燈片 4 和 29 上的最新信息。NeuroSense強調，演示文稿中的新數據並不構成對重要性的承認。該公司建議，該演示文稿的摘要信息應與其向美國證券交易委員會提交的文件和其他公開披露（可能包括新聞稿）一起查看。更新的演示文稿的日期爲2024年1月，Alon Ben-Noon於2024年1月9日代表NeuroSense Therapeutics Ltd.簽署了6-K表格。
有用
沒用